Correlation of Clinical and Dosimetric Parameters With Radiographic Lung Injury Following Stereotactic Body Radiotherapy

被引:8
|
作者
Kishan, Amar U. [1 ]
Wang, Pin-Chieh [1 ]
Sheng, Ke [1 ]
Yu, Victoria [1 ]
Ruan, Dan [1 ]
Cao, Minsong [1 ]
Tenn, Stephen [1 ]
Low, Daniel A. [1 ]
Lee, Percy [1 ]
机构
[1] Univ Calif Los Angeles, Dept Radiat Oncol, David Geffen Sch Med, Los Angeles, CA 90024 USA
关键词
SBRT; fibrosis; lung injury; RADIATION-THERAPY; DENSITY CHANGES; CT APPEARANCE; PHASE-II; CANCER; TUMORS; PNEUMONITIS; RECURRENCE; ACCURACY; MODELS;
D O I
10.1177/1533034614551476
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiographic changes occur in over half of patients treated with stereotactic body radiotherapy (SBRT) to the lung, correlating histopathologically with injury. We quantified radiographic density changes (ie, fibrosis) at 3, 6, and 12 months and investigated the relationship between these volumes and clinical and dosimetric parameters. The study population consisted of patients treated with SBRT to the lung for stage I primary lung cancers (n = 39) or oligometastatic lesions (n = 17). Fractionation schemes included 3 fractions of 12, 14, or 18 gray (Gy) and 4 fractions of 12 or 12.5 Gy prescribed to cover 95% of the planning target volume (PTV). Planning computed tomography (CT) scans were rigidly registered to follow-up CT scans obtained at intervals of 3, 6, and 12 months. Fibrotic volumes were contoured on the follow-up scans. Associations between the volume of fibrosis and clinical and dosimetric parameters were investigated using univariate linear regression. Scans were available for 65 and 47 lesions at 6 and 12 months, respectively. Age, years since quitting smoking, and GOLD Global Initiative for Chronic Obstructive Lung Disease score were significantly associated with increasing volume of fibrosis (P < .05). Total dose, dose per fraction, PTV, and volumetric parameters (V0-V55) were also significantly associated with increasing volumes of fibrosis (P < .01). For dosimetric parameters, the effect was largest for V55. Age, significant smoking history, and GOLD score were significantly associated with increasing volumes of fibrosis following SBRT. In a multivariate model adjusted for age and smoking history, V10 through V50 and PTV size remained significant predictors of fibrotic volume. Further, there is a strong dose-response relationship between the volume of lung exposed to a certain dose and the fibrotic volume. The predominant kinetic patterns of fibrosis demonstrate peaking fibrotic volumes at 6 and 12 months. These results provide insight for expectations of fibrosis after SBRT.
引用
收藏
页码:411 / 418
页数:8
相关论文
共 50 条
  • [31] Dosimetric predictors, of esophageal toxicity after stereotactic body radiotherapy for central lung tumors
    Wu, Abraham J.
    Williams, Eric
    Modh, Ankit
    Foster, Amanda
    Yorke, Ellen
    Rimner, Andreas
    Jackson, Andrew
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 112 (02) : 267 - 271
  • [32] DOSIMETRIC PREDICTORS OF ESOPHAGEAL TOXICITY AFTER STEREOTACTIC BODY RADIOTHERAPY FOR CENTRAL LUNG TUMORS
    Modh, Ankit
    Williams, Eric
    Rimner, Andreas
    Foster, Amanda
    Yorke, Ellen
    Jackson, Andrew
    Wu, Abraham J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S361 - S362
  • [33] Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors
    Regnery, Sebastian
    Eichkorn, Tanja
    Weykamp, Fabian
    Held, Thomas
    Dinges, Lisa-Antonia
    Schunn, Fabian
    Winter, Hauke
    Thomas, Michael
    Debus, Jurgen
    El Shafie, Rami A.
    Adeberg, Sebastian
    Hoerner-Rieber, Juliane
    [J]. CANCERS, 2020, 12 (10) : 1 - 14
  • [34] Radiographic Changes in Lung of Patients Treated with Stereotactic Ablative Body Radiation Therapy and the Dosimetric Correlations
    Wang, Fen
    Park, John
    Kimler, Bruce F.
    Badkul, Rajeev
    Kumar, Parvesh
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S441 - S441
  • [35] Analysis of Dosimetric Verification Results of Stereotactic Body Radiotherapy
    Zhang, X.
    Yang, R.
    Li, J.
    Li, J.
    Wang, J.
    [J]. MEDICAL PHYSICS, 2019, 46 (06) : E610 - E610
  • [36] Clinical Results of Stereotactic Body Radiotherapy for Oligometastatic Lung Tumors
    Shioyama, Y.
    Nomoto, S.
    Ohga, S.
    Nonoshita, T.
    Ohnishi, K.
    Terashima, K.
    Nakamura, K.
    Hirata, H.
    Honda, H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S456 - S457
  • [37] Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial
    Vivek Verma
    Abhijeet R. Bhirud
    Kyle A. Denniston
    Nathan R. Bennion
    Chi Lin
    [J]. Radiation Oncology, 12
  • [38] Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial
    Verma, Vivek
    Bhirud, Abhijeet R.
    Denniston, Kyle A.
    Bennion, Nathan R.
    Lin, Chi
    [J]. RADIATION ONCOLOGY, 2017, 12
  • [39] Clinical Outcomes and Dosimetric Considerations using Stereotactic Body Radiotherapy (SBRT) for Abdominopelvic Tumors
    Barney, B. M.
    Macdonald, O. K.
    de los Santos, L. E. Fong
    Miller, R. C.
    Haddock, M. G.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S313 - S314
  • [40] Survival Impact of Cardiac Dose Following Lung Stereotactic Body Radiotherapy
    Wong, Olive Y.
    Yau, Vivian
    Kang, Julie
    Glick, Daniel
    Lindsay, Patricia
    Le, Lisa W.
    Sun, Alexander
    Bezjak, Andrea
    Cho, B. C. John
    Hope, Andrew
    Giuliani, Meredith
    [J]. CLINICAL LUNG CANCER, 2018, 19 (02) : E241 - E246